Elutia Inc. has disclosed a significant stock option grant to its director, Brigid Makes, in a recent SEC filing. This move is designed to enhance executive retention and align the interests of the board with those of shareholders.

The filing, dated November 12, 2026, reveals that on November 10, 2026, the Board of Directors approved an increase in the grant date value of annual equity awards for non-employee board members to $150,000. Notably, the Executive Chairman's award will be 1.5 times that amount, totaling $225,000. This adjustment is part of the Revised Annual Director Awards, which aim to ensure competitive compensation in the biological products sector.

Background

Elutia Inc., classified under the SIC code 2836 for Biological Products (No Diagnostic Substances), is a company listed on the Nasdaq under the ticker symbol ELUT. The company is incorporated in Delaware and has its business address in Silver Spring, Maryland. Elutia is recognized for its focus on developing innovative biological products.

What the Filing Says

The SEC filing indicates that Brigid Makes was granted stock options for 117,000 shares of Class A Common Stock, with an exercise price set at $0.93. The options will vest fully on the date of the company's 2027 annual meeting of stockholders, contingent upon her continued service through that date. The filing states, "This option was granted on a one-time basis to the non-employee members of the Board equal to 50% of the Revised Annual Director Awards."

Impact

This stock option grant may impact various stakeholders, including shareholders and other board members. For shareholders, aligning the interests of directors with those of the company can potentially enhance company performance and shareholder value. Other companies in the biological products industry may also take note of this strategy as they consider their own compensation packages for executive talent.

What's Next

The filing does not say what happens next.